JP2016525114A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016525114A5 JP2016525114A5 JP2016527033A JP2016527033A JP2016525114A5 JP 2016525114 A5 JP2016525114 A5 JP 2016525114A5 JP 2016527033 A JP2016527033 A JP 2016527033A JP 2016527033 A JP2016527033 A JP 2016527033A JP 2016525114 A5 JP2016525114 A5 JP 2016525114A5
- Authority
- JP
- Japan
- Prior art keywords
- hcv
- interferon
- composition
- compound
- ns5a
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 8
- 108010050904 Interferons Proteins 0.000 claims 5
- 102000014150 Interferons Human genes 0.000 claims 5
- 101800001014 Non-structural protein 5A Proteins 0.000 claims 5
- 229940079322 interferon Drugs 0.000 claims 5
- 125000000217 alkyl group Chemical group 0.000 claims 3
- 230000000694 effects Effects 0.000 claims 3
- 108010047761 Interferon-alpha Proteins 0.000 claims 2
- 102000006992 Interferon-alpha Human genes 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 230000008685 targeting Effects 0.000 claims 2
- 101710200424 Inosine-5'-monophosphate dehydrogenase Proteins 0.000 claims 1
- 102100040018 Interferon alpha-2 Human genes 0.000 claims 1
- 108010079944 Interferon-alpha2b Proteins 0.000 claims 1
- 108060004795 Methyltransferase Proteins 0.000 claims 1
- 101800001019 Non-structural protein 4B Proteins 0.000 claims 1
- 108091005804 Peptidases Proteins 0.000 claims 1
- 239000004365 Protease Substances 0.000 claims 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 claims 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000001188 haloalkyl group Chemical group 0.000 claims 1
- 125000001475 halogen functional group Chemical group 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 229960000329 ribavirin Drugs 0.000 claims 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 230000002195 synergetic effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361847388P | 2013-07-17 | 2013-07-17 | |
| US61/847,388 | 2013-07-17 | ||
| PCT/US2014/046685 WO2015026454A1 (en) | 2013-07-17 | 2014-07-15 | Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis c virus |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016525114A JP2016525114A (ja) | 2016-08-22 |
| JP2016525114A5 true JP2016525114A5 (cg-RX-API-DMAC10.html) | 2017-07-27 |
Family
ID=51293156
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016527033A Pending JP2016525114A (ja) | 2013-07-17 | 2014-07-15 | Ｃ型肝炎ウイルスの治療に使用するためのトリシクロヘキサデカヘキサエン誘導体を含む組み合わせ |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP3021846A1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2016525114A (cg-RX-API-DMAC10.html) |
| CN (1) | CN105555266B (cg-RX-API-DMAC10.html) |
| WO (1) | WO2015026454A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2016527232A (ja) | 2013-07-17 | 2016-09-08 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｈｃｖの治療に使用するためのビフェニル誘導体を含む組み合わせ |
| US10617675B2 (en) | 2015-08-06 | 2020-04-14 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| WO2017076187A1 (zh) * | 2015-11-06 | 2017-05-11 | 江苏豪森药业集团有限公司 | 1,4(1,4)-二苯杂环六蕃-12,43-二基衍生物及其制备方法与应用 |
| WO2017076194A1 (zh) * | 2015-11-06 | 2017-05-11 | 江苏豪森药业集团有限公司 | 具有抑制hcv活性的化合物及其制备方法和应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2438802A (en) | 2005-02-28 | 2007-12-05 | Univ Rockefeller | Structure of the hepatitis C virus NS5A protein |
| US8329159B2 (en) * | 2006-08-11 | 2012-12-11 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| EP2473056A4 (en) * | 2009-09-04 | 2013-02-13 | Glaxosmithkline Llc | CHEMICAL COMPOUNDS |
| US8415374B2 (en) * | 2009-10-12 | 2013-04-09 | Bristol-Myers Squibb Company | Combinations of hepatitis C virus inhibitors |
| US20130157894A1 (en) * | 2010-07-16 | 2013-06-20 | Jin-Hua Sun | Methods to identify combinations of ns5a targeting compound that act synergistically to inhibit hepatitis c virus replication |
| RS55123B1 (sr) * | 2011-05-27 | 2016-12-30 | Achillion Pharmaceuticals Inc | Supstituisani alifani, ciklofani, heterafani, heterofani, hetero-heterafani i metaloceni korisni za lečenje infekcija hepatitis c virusa |
| US9326973B2 (en) * | 2012-01-13 | 2016-05-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
-
2014
- 2014-07-15 WO PCT/US2014/046685 patent/WO2015026454A1/en not_active Ceased
- 2014-07-15 EP EP14748036.2A patent/EP3021846A1/en not_active Withdrawn
- 2014-07-15 CN CN201480050770.5A patent/CN105555266B/zh not_active Expired - Fee Related
- 2014-07-15 JP JP2016527033A patent/JP2016525114A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12018550148A1 (en) | Hepatitis b antiviral agents | |
| JP2014504643A5 (cg-RX-API-DMAC10.html) | ||
| PH12021551116A1 (en) | Functionalized heterocycles as antiviral agents | |
| EA201991174A1 (ru) | Комбинация двух противовирусных препаратов для лечения гепатита c | |
| MX2016012799A (es) | Metodos para tratar el virus de la hepatitis c. | |
| JP2013514359A5 (cg-RX-API-DMAC10.html) | ||
| JP2013507439A5 (cg-RX-API-DMAC10.html) | ||
| ES2572329A2 (es) | Combinacion de al menos dos agentes antivirales de accion directa y ribavirina pero no interferon, para uso en el tratamientodel vhc | |
| JP2016513703A5 (cg-RX-API-DMAC10.html) | ||
| JP2016505637A5 (cg-RX-API-DMAC10.html) | ||
| JP2015024998A5 (cg-RX-API-DMAC10.html) | ||
| GEP20247600B (en) | B-D-2'-DEOXY-2'a-FLUORO-2'-B-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT | |
| EA202190602A3 (ru) | 2'-замещенные-n6-замещенные пуриновые нуклеотиды для лечения вызванных рнк-вирусом заболеваний | |
| PH12014500385A1 (en) | Benzofuran compounds for the treatment of hepatitis c virus infections | |
| RU2017103656A (ru) | Производные изоиндолинона, полезные в качестве противовирусных средств | |
| RU2015114566A (ru) | Способы лечения гепатита с | |
| MX389088B (es) | Métodos para tratar el vhc. | |
| PH12018502735A1 (en) | Liver delivery-based antiviral precursor drug nucleoside cyclophosphate compound and use thereof | |
| WO2015160907A3 (en) | Potent and selective inhibitors of hepatitis c virus | |
| JP2014058509A5 (cg-RX-API-DMAC10.html) | ||
| MX2016012722A (es) | Metodos para tratar el virus de la hepatitis c. | |
| JP2016527232A5 (cg-RX-API-DMAC10.html) | ||
| JP2015514807A5 (cg-RX-API-DMAC10.html) | ||
| EA201692514A1 (ru) | Фармацевтические композиции на основе софосбувира и рибавирина с модифицированным высвобождением | |
| Ozaras et al. | Occult hepatitis B and risk of reactivation after hepatitis C treatment with direct-acting antivirals |